Trepulmix 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0016 
C.I.11.z - Introduction of, or change(s) to, the 
13/09/2023 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0017/G 
This was an application for a group of variations. 
25/07/2023 
n/a 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.b.5.b - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Addition of a new test(s) and limits 
IA/0015 
B.II.e.7.b - Change in supplier of packaging 
11/07/2023 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
N/0012 
Minor change in labelling or package leaflet not 
19/01/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/3013/
Periodic Safety Update EU Single assessment - 
12/01/2023 
n/a 
PRAC Recommendation - maintenance 
202205 
treprostinil 
IAIN/0011/G 
This was an application for a group of variations. 
02/12/2022 
n/a 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IB/0009 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
22/06/2022 
n/a 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
PSUSA/3013/
Periodic Safety Update EU Single assessment - 
13/01/2022 
n/a 
PRAC Recommendation - maintenance 
202105 
treprostinil 
IAIN/0008 
B.II.b.2.c.1 - Change to importer, batch release 
20/09/2021 
22/03/2022 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IA/0007/G 
This was an application for a group of variations. 
23/08/2021 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0005/G 
This was an application for a group of variations. 
13/07/2021 
n/a 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.c.z - Container closure system of the AS - Other 
variation 
B.I.c.3.a - Change in test procedure for the 
immediate packaging of the AS - Minor changes to 
an approved test procedure 
B.I.z - Quality change - Active substance - Other 
variation 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
Page 4/7 
 
 
 
 
 
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
B.I.a.4.f - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
or replacement of an in-process test as a result of a 
safety or quality issue 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
Page 5/7 
 
 
 
 
 
 
IB/0004 
C.I.z - Changes (Safety/Efficacy) of Human and 
09/03/2021 
22/03/2022 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
PSUSA/3013/
Periodic Safety Update EU Single assessment - 
14/01/2021 
n/a 
PRAC Recommendation - maintenance 
202005 
treprostinil 
II/0002/G 
This was an application for a group of variations. 
06/11/2020 
n/a 
B.I.a.1.b - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a manufacturer of the AS supported 
by an ASMF 
B.I.b.2.c - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure for a reagent, which 
does not have a significant effect on the overall 
quality of the AS 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.f - Replacement or addition of a 
manufacturing site for part or all of the 
manufacturing process of the FP - Site where any 
manufacturing operation(s) take place, except batch 
release, batch control, and secondary packaging, for 
sterile medicinal products (including those that are 
aseptically manufactured) excluding biological/ 
immunological medicinal products 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
control/testing takes place 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0001 
C.I.z - Changes (Safety/Efficacy) of Human and 
12/06/2020 
n/a 
Veterinary Medicinal Products - Other variation 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
